PLRZ

Polyrizon Ltd.

Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. L3· CIK 0001893645 Healthcare & Medical Devices

$8.96 +0.23 (+2.66%)

Oct 26 4:00 PM ET · prev $8.73

Market cap

$21.2M

Nano cap

1 year

+37.0%

from $6.54 · Oct 27

30 days

−13.5%

from $10.36

52-week range

$3.13–17.17

−48% from high · low Nov 26

Avg volume 20D

24.0K

Oct 14 spike 90.2K

Short interest

🔒 Subscribers only

Insider net

−$132.6K

0 buyers · 4 sellers · 12 mo

Filing reports

analyzed by SecBot

SecBot read BEARISH 8 reports · 90 days

Balance 5 bearish · 1 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 6/8

Strongest BULLISH Polyrizon announced the enrollment of the first patient in its U.S. clinical study for NASARIX (PL-14), an…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Mar 30 to Mar 31 2 days of insider sells: $132.6K by 4 insiders, avg $11.38
E Apr 8 Offering: Polyrizon Ltd. Announces Closing of $3.5 Million Registere…
X Aug 14 Short interest jumps 48.8% to 94.2K
X Aug 31 Short interest falls 27.2% to 68.6K
R Sep 4 Polyrizon Ltd. filed a 6-K disclosing a securities purchase agreemen…
R Sep 4 Polyrizon Ltd. filed a 424B5 prospectus supplement for a registered…
R Sep 4 Polyrizon Ltd. closed a registered direct offering and concurrent pr…
R Sep 22 Polyrizon announced the enrollment of the first patient in its U.S.…

Signal stack

Where each data set points today.

InsidersBEARISH

4 insiders sold $132.6K.
TrendDOWNTREND

16% below its 50-day average.

Who's buying

13F

Top holder	Shares	Value
HRT FINANCIAL LP	21,363	$269.0K
MORGAN STANLEY	3	$38.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 5, 2026 SEC

Polyrizon filed a new U.S. divisional patent application (No. 19/823,285) covering its proprietary mucoadhesive…

6-K — Impact 3/10

Oct 5, 2026 Other

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential appl

Oct 2, 2026 SEC

The SEC declared effective Polyrizon Ltd.'s F-1 registration statement (File No. 333-299014) on October 1, 2026…

EFFECT — Impact 5/10

Sep 22, 2026 Press

Polyrizon announced the enrollment of the first patient in its U.S. clinical study for NASARIX (PL-14), an…

Impact 6/10

Sep 18, 2026 SEC

Polyrizon Ltd. filed a new F-1 registration statement to register 404,166 ordinary shares for resale by Armistice…

F-1 — Impact 5/10

Sep 4, 2026 Press

Polyrizon Ltd. closed a registered direct offering and concurrent private placement, raising approximately $4.0…

Impact 6/10

Mar 31, 2026 Insider

Adler Oz sold 3,292 shares

Director @ $12.05 ($39.7K)

Mar 31, 2026 Insider

Izraeli Tomer sold 500 shares

Chief Executive Officer @ $11.85 ($5.9K)

Insider ledger

Form 4

bought · 0 insiders

$132.6K

sold · 4 insiders

Date	Insider	Type	Value
Mar 31, 2026	Adler Oz Director	SELL	$39.7K
Mar 31, 2026	Izraeli Tomer Chief Executive Officer	SELL	$5.9K
Mar 31, 2026	Carmel Liron Director	SELL	$11.6K
Mar 30, 2026	Carmel Liron Director	SELL	$1.1K
Mar 30, 2026	Izraeli Tomer Chief Executive Officer	SELL	$42.5K
Mar 30, 2026	Turgeman Tidhar Chief Technology Officer	SELL	$31.8K